
Most AI tools suffer from ‘hallucination'
Most artificial intelligence systems suffer from the flaw of 'hallucination' and are not meant for India's small enterprises in the manufacturing sector, deep-tech company Vexoo Labs has said and claimed its AI solutions are for the 'real world'.
'The focus on factual accuracy is both rare and crucial,' said Ajay Kumar, senior business leader, AI Evangelist and a board advisor at Vexoo Labs. He said most AI tools today are built for showcase, not for reliability. In the industrial alleys of Rajkot, the looms of Tiruppur, and the machining units of Coimbatore, India's small and mid-sized manufacturers are facing a silent crisis, he noted. 'It's not rising input costs or labour shortages alone - it's the growing complexity of data, and the absence of any reliable AI system to help make sense of it,' Kumar said.
According to Kumar, despite the global boom in artificial intelligence, 'most systems on the market today suffer from a dangerous flaw: hallucinations — confidently delivering factually incorrect information. For India's MSMEs, where decisions have direct operational and financial consequences, this isn't just a flaw, it's a liability.'
He further said that even at global AI showcases like Super AI, dozens of platforms claim to be transformative. But behind the gloss lies a glaring truth — most are built atop general-purpose language models that continue to hallucinate. 'While the world chases scale and speed, accuracy has quietly fallen through the cracks,' he said, adding, Vexoo Labs' reasoning-first architecture, compact models, and local execution capabilities make it especially relevant for Tier-II and Tier-III cities, where India's manufacturing momentum truly lies. He said the company's focus on trustworthy AI for real-world India is already resonating across enterprise and public sector conversations.
'We didn't set out to build a shinier chatbot. We set out to solve the core flaw in AI itself — hallucinations,' added Aditya Vardhan, co-founder of Vexoo Labs. 'Manufacturers in Ludhiana, Surat or Bhiwadi shouldn't have to rely on guesswork. They deserve
AI that answers clearly, correctly, and fast — and that's what we're building at Vexoo Labs,' Vardhan explained.
He said that as India eyes to become a $5-trillion economy, the 'real digital leap may not come from big cities or billion-parameter models, but from trust-first intelligence deployed deep within India's industrial backbone'.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


News18
3 hours ago
- News18
UP's Much-Awaited Pharma Park All Set To Become A Reality By 2027
Last Updated: With construction underway on over 350 acres in the first phase, the project is expected to catalyse investments worth over Rs 12,000 crore Uttar Pradesh's much-awaited Pharma Park is all set to become a reality by 2027 as the state government begins work on North India's first bulk drug and formulation hub in Lalitpur. With construction underway on over 350 acres in the first phase, the project is expected to catalyse investments worth over Rs 12,000 crore and boost UP's bid to become a national pharmaceutical manufacturing powerhouse. Spearheaded by the Uttar Pradesh State Industrial Development Authority (UPSIDA), the Lalitpur Bulk Drug Pharma Park is part of UP government's move to make the state self-reliant in bulk drug and Active Pharmaceutical Ingredient (API) production, while transforming Bundelkhand into an industrial powerhouse. Spread over 1,472 acres, the park is being developed in phases. Construction work for the first phase, covering 353 acres, is already underway. According to UPSIDA, environmental clearances have been secured, and land allotment to industries has begun. UPSIDA regional manager Sandeep Kumar confirmed that four pharmaceutical companies have submitted applications to set up units within the park. Of these, IJ Pharma and Badariya Pharma have already been allotted plots, while Riddhi Siddhi Pharma and JBJM Pharmaceuticals are in the final stages of the allotment process. 'Contracts with two companies are complete, while documentation for the remaining two is ongoing," Kumar said. The project has already caught the attention of prominent investors. During a recent investment roadshow in Ahmedabad, several pharma companies signed key proposals. UPSIDA CEO Mayur Maheshwari stated that the authority will conduct similar outreach initiatives in Mumbai, Chandigarh, and Hyderabad to attract more pharma players. Maheshwari described the park as a 'state-of-the-art plug-and-play facility" tailored to meet global standards. 'All utilities—electricity, water, waste management—are being designed for 24/7 industrial support. The entire park will be based on Zero Liquid Discharge (ZLD), ensuring that no untreated wastewater leaves the premises," he said. The park's underground utility network will include steam and solvent recovery systems, climate-controlled warehouses, and dedicated logistics corridors. A waste management system with a 3.53 TPD capacity, 33/11 KV sub-stations, and a 75 TPH steam distribution system will be in place to ensure operational efficiency. Safety and support infrastructure are also in focus. Plans include CCTV surveillance, boundary fencing, emergency service centers, and in-house skilling centres for local manpower training. Affordable housing for workers and executives is also under development within the premises. Investor Incentives UPSIDA has rolled out a special industrial land allotment scheme for the pharma park. Plots are priced at Rs 1,914 per square meter, with an additional 2 per cent discount for one-time payment. These rates, according to UPSIDA officials, are highly competitive compared to other pharma hubs in India and are expected to attract significant interest from small and mid-sized pharmaceutical players. 'Infrastructure, regulatory clearances, and affordability are all aligned to offer investors a compelling alternative to Gujarat or Hyderabad," said Maheshwari. The Lalitpur Pharma Park has already begun attracting significant industrial investments. CSL Life Sciences Pvt Ltd has proposed a Rs 200 crore investment to set up two manufacturing units—an IV Bottle Plant and an Oral Solid Dosage (OSD) Plant—spread over 5 to 7 acres. These units are expected to generate employment for over 250 people and become operational within the next two years. In addition, Mediheath Diagnostic Pvt Ltd is establishing a healthcare and diagnostic unit on a 4,200-square-meter plot, while Gaman Irradiation has announced plans to invest Rs 35 crore in a skin treatment and irradiation facility that is projected to create around 150 jobs within 24 to 36 months. Another major entrant, Obmed Pharma, has committed Rs 200 crore for setting up a formulation unit on a five-acre plot, which is expected to employ approximately 100 workers. These early investments signal strong industry confidence in the project and are expected to accelerate momentum as the park gains visibility on the national pharmaceutical landscape. Strong Connectivity The Lalitpur pharma park benefits from excellent multi-modal connectivity. The site is linked via MDR 35B, with NH-44 and NH-539 nearby, and is connected by rail through Tikamgarh and Lalitpur Junction. Air connectivity is facilitated via Khajuraho Airport (125 km away) and Lucknow Airport (385 km away). The proximity to the Jhansi node of the Uttar Pradesh Defence Corridor adds strategic value, as does its alignment with the state's broader goal of becoming a $1 trillion economy. According to Maheshwari, the Lalitpur pharma park is being developed in collaboration with leading national institutions like IIT, DRDO, and private consultancy firm Assystem India Limited, which has experience working on world-class pharma parks in Visakhapatnam. top videos View all 'We're not just matching global standards — we're aiming to surpass them," he said. 'Uttar Pradesh is well-positioned to fill the gap left after tax benefits in Himachal Pradesh ended. With the right policies, infrastructure, and investor confidence, we're ready to take the lead in pharma manufacturing." With construction in full swing, the park is expected to show physical results within two years, potentially transforming Lalitpur into India's premier bulk drug manufacturing hub. First Published: News india UP's Much-Awaited Pharma Park All Set To Become A Reality By 2027


Time of India
13 hours ago
- Time of India
Which stocks should traders buy as indices hit a nine-month high?
As benchmark indices hit a nine-month high in the last week of June, traders are looking to ride the bullish wave. A look at some of the stock futures that have seen higher-than-average rollovers to the July series and poised to move up further. HPCL CMP: Rs 439 Change in Open Interest in July Series: 9% Change in Price in July Series: 4.3% Decline in crude oil prices has supported oil marketing companies move higher, said Chandan Taparia, head of technical and derivatives research at Motilal Oswal Financial Services . 'The stock has seen meaningful long additions on Friday and has been making higher lows for the last 4 trading sessions,' he said. The stock also gave a consolidation breakout after 35 long weeks. Traders can buy the contracts with support at Rs 425 for an upside target towards Rs 465 levels. ULTRATECH CEMENT CMP: Rs 12,234 Change in Open Interest in July Series: -2.81% Change in Price in July Series: +1.96% Live Events The stock rose due to short covering on Friday, said Vipin Kumar, AVP, derivatives and technical research at Globe Capital Market. 'On charts, it is trading on the verge of a fresh breakout from a year-long congestion zone at Rs 10,130-12,396. Considering its current chart structure and derivatives data, we expect the stock to move northward in near term and test Rs 13,500- Rs 14,000 levels,' he said. Kumar suggested traders buy its July futures with a stop loss at Rs 11,400. POWER GRID CORP CMP: `299 Change in Open Interest in July Series: -1% Change in Price in July Series: +1.60% Technically, it is well placed on multiple time frames and has bounced back sharply from its price support of `285, said Kumar. 'All the parameters are indicating higher probability of positive momentum in this stock in the near term,' he said. Hence, we suggest traders to go long till it is holding above `284 levels and expect it to test `315-`325 in near term.' INDRAPRASTHA GAS CMP: Rs 213.85 Change in Open Interest in July Series: 13% Change in Price in July Series: 3% Indraprastha has given a consolidation breakout on daily and weekly charts with a decisive close above Rs 214 levels, said Taparia. 'The stock has seen support-based buying with addition in option interests, which clearly indicates that longs are being added at current juncture for next move,' he said. Traders can buy Indraprastha contracts with support at Rs 207 for an upside target towards Rs 228. APOLLO HOSPITALS CMP: Rs 7,305 Change in Open Interest in July Series: 0.38% Change in Price in July Series: 2.71% Sudeep Shah, head, technical and derivative research at SBI Securities, said, on daily chart, stock has registered a breakout supported by robust volume participation— signalling strong buying interest. 'This breakout not only validates the underlying strength but also marks shift in sentiment after consolidation,' he said. Shah recommends stock in the zone of Rs 7,320-Rs 7,280 with a stop loss of Rs 7,080, for a target of Rs 7,750. HDFC LIFE INSURANCE CMP: Rs 807.35 Change in Open Interest in July Series: -6.28% Change in Price in July Series: 0.34% Shah said the stock has recently given a 'stage-2 cup pattern' breakout on a daily scale. 'This breakout is confirmed by robust volume. Currently, the stock is trading above its short and longterm moving averages, and these averages are edging higher, which is a bullish sign,' he said. He recommends accumulating the stock in the zone of `810-`800 with a stop loss of `780, for a target of `870 in the short term.


Time of India
19 hours ago
- Time of India
Infosys files fresh charges against Cognizant in the US court, report names two senior Cognizant employees
Representative Image The ongoing legal battle between Indian IT giant Infosys Ltd and US-based Cognizant Technology Solutions has intensified, with Infosys now accusing two senior Cognizant executives of orchestrating a deliberate effort to poach key personnel critical to its healthcare platform, Helix, according to a report by Mint. Infosys has named Cognizant's Chief People Officer Kathryn Diaz and Surya Gummadi, president of Cognizant's Americas division, as being allegedly involved in targeting and hiring key Infosys executives, hampering the development of Helix, a platform positioned as a rival to Cognizant's TriZetto . The accusations follow earlier claims against Cognizant CEO Ravi Kumar S , a former Infosys president, whom Infosys accused in a January 9 court filing of stalling Helix's rollout while negotiating his move to Cognizant in 2022. The report said that in a June 13 joint filing to a Dallas court, Infosys alleged that Kumar, after becoming Cognizant's CEO in January 2023, appointed Diaz as Chief People Officer. During her tenure, Cognizant allegedly targeted Infosys' Helix platform by hiring Shveta Arora, now Cognizant's consulting head, between October and December 2023, and Ravi Kuchibhotla, currently Cognizant's chief strategy officer, in August 2024. Both executives previously worked on Helix at Infosys. Cognizant rejects Infosys charges by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Sua próxima viagem te espera Azul Linhas Aéreas Saiba Mais Undo 'Cognizant targeted our key executives involved in the Helix platform, which has significantly disrupted its development,' Infosys stated in its filing, as cited by the report. The company further claimed that both Diaz and Gummadi possess documents relevant to the case, reinforcing allegations of targeted interference. Cognizant swiftly rejected the accusations, reportedly saying that 'Infosys' continued attempts to mislead do not change the fact that it has been caught red-handed stealing Cognizant's intellectual property.' The company also clarified that Diaz was appointed well after Kumar joined Cognizant, dismissing the poaching claims. The dispute traces back to August 2024, when Cognizant accused Infosys of misappropriating trade secrets related to its healthcare software. Infosys denied the allegations and filed counterclaims, arguing Cognizant failed to specify the stolen information. The escalating feud underscores tensions between the two IT giants as they compete in the lucrative healthcare technology market. AI Masterclass for Students. Upskill Young Ones Today!– Join Now